TearClear Announces Successful Completion of Pre-IND Meeting With the FDA for a Preservative-Free Multi-Dose Delivery of Latanoprost for the Treatment of Glaucoma

TearClear announced successful completion of pre-IND (investigational new drug) meeting with the FDA regarding the development plan for the preservative-free multi-dose delivery of a proprietary latanoprost formulation, including the clinical study design for the registration study. 

“We are pleased with the outcome of the pre-IND meeting and look forward to preparing the IND filing and commencing our pivotal registration trial in 2021,” Robert Dempsey, Chief Executive Officer, TearClear, said in a company news release. “The successful completion of this engagement with the FDA is an important milestone for the company and provides clarity and confidence as we advance our lead clinical program in the U.S.”